Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy

Clarice Groeneveld; Jacqueline Fontugne; Luc Cabel; Isabelle Bernard-Pierrot; François Radvanyi; Yves Allory; Aurélien de Reyniès

doi:10.1016/j.ejca.2021.01.036

Journal articles

Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy

Clarice Groeneveld Jacqueline Fontugne Luc Cabel Isabelle Bernard-Pierrot ¹ François Radvanyi ¹ Yves Allory Aurélien de Reyniès

1 Centre de recherche de l'Institut Curie [Paris]

Document type :

Journal articles

Domain :

Life Sciences [q-bio] / Cancer

Complete list of metadata

https://hal-cnrs.archives-ouvertes.fr/hal-03453779
Contributor : Isabelle Bernard-Pierrot Connect in order to contact the contributor
Submitted on : Sunday, November 28, 2021 - 7:23:19 PM
Last modification on : Monday, November 29, 2021 - 3:06:18 AM

HAL-CNRS

Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy

Identifiers

Collections

Citation

Export

Metrics

HAL-CNRS

Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy

Identifiers

Collections

Citation

Export

Share

Metrics